Salvarx Share Discussion Threads

[fig1] 03/3/2017 13:48

2-3 year view needed here Spector.Good luck to you.Fig.

[spectoacc] 03/3/2017 11:20

Drifting nonetheless, and probably going to drift further, but averaged a few this morning. News will come on it, just don't know when.

[phil1969] 02/3/2017 07:44

and no AIM dilution

[spectoacc] 02/3/2017 07:29

Not learned a lot from this morning's restructuring RNS - warrant conversion at 35.5p is fine, and a reminder that 2 people hold over 73% of the co. "If" they do have some success, it'll be interesting seeing people chasing the remaining 27%.

[the stigologist] 02/3/2017 07:24

Delayed dilution by another name is still dilution

[the stigologist] 28/2/2017 23:57

Whineyfroth saying placing ahoy

[fig1] 28/2/2017 10:25

Nice to see the promised diversification of interests at SalvaRx.Fig.

[phil1969] 28/2/2017 08:42

Nice collaboration shame it hasn't created any interest today.

[kingston78] 06/2/2017 22:44

The price action is very positive. Some people in the know are snapping up the shares in anticipation of good news flow.

The share price is likely to move up to a higher range above 40 p soon.

[kingston78] 03/2/2017 11:37

Profit taking is bound to happen as the anticipated news is not yet announced, but I think the price will move up again to a new height.

[phil1969] 03/2/2017 08:00

MMs have only marked it down a penny so it will take continuous selling to move the price downwards. I suspect the buyer is still there waiting to see if they can pick up cheap stock. If not, the buying direct from market and AT trades will continue and I suspect we can look forward to an update from the more lucrative iOX instead.

[kristini2] 03/2/2017 07:52

To be fair they may not have been aware of the moneyweek comment until this week

i feel this may hold today, or not fall too sharply

[spectoacc] 03/2/2017 06:58

Only taken them 7 days to release the clarification! Still - changes nothing except timescale, and may even build up a little publicity.

[the stigologist] 02/2/2017 16:54

02 February 2017

SalvaRx Group plc

("SalvaRx" or "the Company")

Intensity Therapeutics Inc.

The Company notes the recent article in MoneyWeek Magazine about SalvaRx and Intensity Therapeutics Inc., ("Intensity") in which the Company has an 8.5 per cent. interest. The article incorrectly stated that Intensity had dosed its first patient in clinical trials. Intensity expects to dose its first patient shortly at which point a further notification will be made by SalvaRx which will contain full details of the trial including the timeframe for results.

[joemillion] 02/2/2017 16:51

RNS - first patient NOT dosed in clinical trials recently. Appears Moneyweek got it wrong - as have many buyers that have no doubt piled in here upon reading this article!Hopefully this won't have a significant impact on the share price tomorrow...

[phil1969] 02/2/2017 15:33

News is long overdue. They've so many projects in the pipeline plus possible clinical trial results due mentioned in MoneyWeek interview suggesting only 2-3 weeks before knowing results. Volume increased along with share price on Monday I presume as a result of interview. Then the usual lull. Now we have an order being filled and MM's having to take them off the offer with AT trades. Always a positive sign.

[kingston78] 02/2/2017 15:26

There must be some good news to be announced soon. I have held onto this share because I had faith in the management and their track record.

[fig1] 02/2/2017 14:47

Good place to be Phil.(so far!)Fig.

[phil1969] 02/2/2017 14:46

I'm in :-)

[fig1] 02/2/2017 13:31

Holy smoke!!!Fig.

[fig1] 02/2/2017 12:27

Plenty of buying still going on.Hope the punters aren't let down.Fig.

[spectoacc] 01/2/2017 15:13

News coming soon on the first human trial from Intensity Therapeutics - INT230-6.

They've fingers in other pies but the corporate presentation from last September is a useful starting point when looking at the co.